Symbols

IMNM

Immunome·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 3

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Beats Expectation

Bearish Abandoned Baby

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMNM

Immunome, Inc.

A biopharmaceutical company that develops antibody therapeutics for the treatment of cancer and infectious diseases

Industry

Pharmaceutical

Established Date

12/02/2015

Listing Date

10/02/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

177

Fiscal Year Ends

12-31

Website

www.immunome.com

Security Type

Common stock

Office address

18702 N. Creek Parkway, Suite 100, Bothell, WA 98011

Business

Introduction

Immunome, Inc., was incorporated as a Pennsylvania corporation on March 2, 2006 and converted to a Delaware corporation on December 2, 2015. The company is a biotechnology company focused on the development of targeted tumor therapies. Immunome is committed to building a diverse portfolio of differentiated clinical assets to improve the quality of life of cancer patients. At the core of its strategy is expertise in the discovery, design, development, production and commercialization of antibody-drug conjugates and other oncology therapies. Immunome is advancing a R&D pipeline that includes multiple clinical and preclinical assets, demonstrating its commitment to innovation in the oncology space.

Company Financials

EPS

IMNM has released its 2025 Q4 earnings. EPS was reported at -0.76, versus the expected -0.58, missing expectations. The chart below visualizes how IMNM has performed over recent quarters, highlighting trends in earnings surprises.